Spark’s de­liv­ery vec­tor trig­gers an­oth­er trou­bling im­mune re­ac­tion, but R&D team main­tains he­mo­phil­ia B ef­fi­ca­cy

One month af­ter Spark Ther­a­peu­tics $ONCE spooked its in­vestors with the news of one im­mune re­ac­tion to its gene ther­a­py in a small he­mo­phil­ia B study, its in­ves­ti­ga­tors turned up at ASH to add one more case to con­cern its back­ers. But the biotech wasn’t un­pre­pared, com­ing back with ev­i­dence that they were still able to con­trol the im­mune re­ac­tion to SPK-9001 while all but one of 9 pa­tients clear­ly re­mained free of bleeds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER